Skip to main content
Premium Trial:

Request an Annual Quote

Waters to Start Mass Spec Center with U of Warwick

NEW YORK (GenomeWeb News) – Waters will collaborate with the University of Warwick in research focused on developing and supporting the growth and adaptation of novel mass spectrometry technologies, including Waters' Synapt High Definition MS system.

The collaborative research agreement involves the establishment of The Waters Centre for BioMedical Mass Spectrometry at the University of Warwick, which will serve as a center of excellence in mass spectrometry techniques.

The company said that the "agreement paves the way for research projects leading to meaningful impact for analysts using biomedical mass spectrometry, validated by peer-reviewed publications, presentations at international conferences and an outreach education program."

The center will serve as a resource through which scientists can adopt cutting edge LC/MS-based techniques in life science, it said.

"I believe that this partnership between a proven technology leader and a leading research focused University will provide a platform for the development of many exciting new projects," James Scrivens, of the Department of Biological Sciences at the University of Warwick, said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.